Global Blood gains on 90-day sickle cell data

Global Blood Therapeutics Inc. (NASDAQ:GBT) gained $2 to $24.15 on Friday after newly presented 90-day data showed sickle disease candidate GBT440 led to durable reductions in hemolysis in an

Read the full 294 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE